Phase 1b/2a Study Evaluates SNIPR001 with Levofloxacin in HSCT Patients Harboring FQR E. coli

SNIPR Biome Aps. is investigating the safety, PK/PD, and preliminary efficacy of SNIPR001 administered with standard levofloxacin in allogeneic HSCT recipients colonized with fluoroquinolone-resistant E. coli. This randomized, double-blind trial in New York aims to assess whether SNIPR001 can enhance outcomes in hematologic malignancy patients facing antibiotic-resistant infections pre-transplant.